Can painkillers quiet the bladder? Acetaminophen/ibuprofen and catheter-related bladder discomfort

Article information

Korean J Anesthesiol. 2026;.kja.261191
Publication date (electronic) : 2026 October 16
doi : https://doi.org/10.4097/kja.261191
Department of Anesthesiology and Pain Medicine, Chosun University Hospital, Chosun University College of Medicine, Gwangju, Korea
Corresponding author: Ki Tae Jung, M.D., Ph.D. Department of Anesthesiology and Pain Medicine, Chosun University Hospital, 365 Pilmun-dearo, Donggu, Gwangju 61453, Korea Tel: +82-62-220-3223 Fax: +82-62-223-2333 Email: mdmole@chosun.ac.kr
Received 2026 September 28; Accepted 2026 October 6.

Catheter-related bladder discomfort (CRBD) is a common problem associated with intraoperative urinary catheterization. Patients complain of suprapubic discomfort, an urge to void, or a burning sensation in the post-anesthesia care unit (PACU), and severe symptoms may lead to agitation, attempts to remove the catheter, and aggravated postoperative pain [1]. Many preventive agents, such as antimuscarinics, gabapentin, ketamine, dexmedetomidine, nefopam, lidocaine, and peripheral nerve blocks, have been studied [1]. However, a recent network meta-analysis reported that most trials were small and heterogeneous, and that more than half had an unclear or high risk of bias [1]. Urinary catheterization can cause inflammation and mucosal injury to the bladder, increasing prostaglandin synthesis via cyclooxygenase (COX). Prostaglandins induce detrusor contraction and activate bladder C fibers [2]. Therefore, COX inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs) might reduce CRBD. In patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP), a single intraoperative dose of ketorolac reduced the incidence of moderate-to-severe CRBD in the PACU from 50.8% to 21.5% [2]. An intravenous fixed-dose combination (FDC) of acetaminophen and ibuprofen has been used for postoperative analgesia [3]. These two drugs are expected to play different roles because ibuprofen primarily inhibits peripheral prostaglandin synthesis, whereas acetaminophen exerts predominantly central analgesic effects [3]. However, little is known about whether this combination is effective for reducing symptoms of CRBD.

The current edition of the Korean Journal of Anesthesiology includes a study conducted by Park et al. [3] on this question. In this double-blind, randomized, three-arm trial, 172 adults undergoing elective RALP received an FDC of acetaminophen 1 g and ibuprofen 300 mg, acetaminophen 1 g alone, or normal saline at the start of fascial closure. The incidence of moderate-to-severe CRBD on PACU arrival was 46.6% in the FDC group and 59.6% in both the acetaminophen alone and placebo groups; however, the difference was not statistically significant (P = 0.3). Moderate-to-severe CRBD decreased over time in all groups and became uncommon by 6 h, without a consistent difference among the groups. The FDC did not reduce pain scores, 24-h opioid consumption, or postoperative nausea and vomiting, and did not improve patient satisfaction or the quality of recovery.

This study tested an FDC containing two drugs with different roles for preventing CRBD in a relatively large randomized controlled trial; however, the results did not show a significant benefit of the FDC for preventing moderate-to-severe CRBD after RALP. The odds ratio for moderate-to-severe CRBD with placebo compared with the FDC was 1.70 (95% CI [0.87–3.43]) [3], which does not rule out a clinically meaningful benefit of the FDC. The study also showed how CRBD changed during the first 6 h after RALP in a cohort managed with a standardized analgesic protocol. These results may provide useful descriptive data for planning future trials in similar RALP settings.

The results of the present study differ from those of the previous ketorolac trial, in which a single dose of ketorolac administered to patients undergoing RALP reduced the incidence of moderate-to-severe CRBD by more than half and also improved early pain scores, 24-h opioid requirement, and patient satisfaction [2]. Several implications can be drawn from these differences. The discrepancy in the results of the two trials may reflect differences not only in the drugs and doses but also in the duration of surgery, anesthetic management, and baseline severity of CRBD. Compared with the ketorolac trial [2], in the present study [3], the duration of surgery was shorter, desflurane was the main anesthetic agent used, and severe CRBD was rare. The authors point out that the FDC does not directly inhibit muscarinic receptor-mediated detrusor contraction, which is the main mechanism underlying CRBD [3]. The lack of effect on pain scores and opioid consumption suggests that the analgesic effect of the FDC at the dose used was limited in this study setting. The elimination half-lives of acetaminophen and ibuprofen in the FDC are approximately 2.4 and 1.9 h, respectively [4], and mild CRBD was still present in more than half of the patients at 6 h. Therefore, a single intraoperative dose may provide insufficient pharmacologic coverage for symptoms persisting beyond the PACU. Moreover, tramadol, which has antimuscarinic action and can prevent CRBD [5], was used as a rescue medication in the PACU and was administered to all patients in the ward every 8 h [3]. This may have reduced the differences in the effects of the intervention among the groups after PACU arrival.

The present results do not necessarily mean that NSAIDs are ineffective for preventing CRBD. Rather, they suggest several directions for future studies. First, the drug, dose, and duration of treatment should be selected according to the characteristics of the patient and the surgery. In a pilot trial, intravenous acetaminophen administered every 4 h for 12 h after transurethral resection of bladder tumors reduced CRBD scores at 8 h and the need for additional analgesics [6]. A scheduled regimen of the FDC would test the effect of longer drug exposure. Second, peripheral nerve blocks have been reported to reduce CRBD [1], and the authors suggest the use of multimodal strategies incorporating regional techniques that attenuate afferent input from the bladder and abdominal wall [3]. Thus, further studies are required to investigate how NSAIDs or the FDC could be combined with antimuscarinic agents or regional techniques. Third, the effect of these drugs should also be evaluated in surgeries with a higher incidence of CRBD, such as transurethral procedures.

Park et al. [3] evaluated an intravenous FDC of 2 analgesics, acetaminophen and ibuprofen, for preventing CRBD in a well-designed and clearly reported trial. A single intraoperative dose of the FDC did not significantly reduce moderate-to-severe CRBD after RALP. These results may help clinicians choose an appropriate analgesic strategy and may be useful in designing future trials. Scheduled and multimodal strategies that target different mechanisms are needed for the management of CRBD, and this study may serve as a basis for such studies.

Notes

Funding

None.

Conflicts of Interest

Ki Tae Jung has been an editor for the Korean Journal of Anesthesiology since 2020. However, he was not involved in any process of review for this article, including peer reviewer selection, evaluation, or decision-making. There were no other potential conflicts of interest relevant to this article.

References

1. Ren J, Yu T, Tian Y, Luo G. Comparative effectiveness of interventions for managing urological postoperative catheter-related bladder discomfort: a systematic review and network meta-analysis. BMC Urol 2023;23:29. 10.1186/s12894-023-01195-9. 36869313.
2. Park JY, Hong JH, Yu J, Kim DH, Koh GH, Lee SA, et al. Effect of ketorolac on the prevention of postoperative catheter-related bladder discomfort in patients undergoing robot-assisted laparoscopic radical prostatectomy: a randomized, double-blinded, placebo-controlled study. J Clin Med 2019;8:759. 10.3390/jcm8060759. 31146434.
3. Park HS, Hong JH, Choi WJ, Jang DM, Koh WU. Efficacy of an intravenous acetaminophen/ibuprofen fixed-dose combination for postoperative catheter-related bladder discomfort in patients undergoing robot-assisted laparoscopic prostatectomy: a double-blinded, randomized, placebo-controlled study. Korean J Anesthesiol 2026. Advance Access published on Apr 1, 2026. https://doi.org/10.4097/kja.25833. 10.4097/kja.25833. 41918243.
4. Atkinson HC, Stanescu I, Frampton C, Salem II, Beasley CP, Robson R. Pharmacokinetics and bioavailability of a fixed-dose combination of ibuprofen and paracetamol after intravenous and oral administration. Clin Drug Investig 2015;35:625–32. 10.1007/s40261-015-0320-8. 26334726.
5. Bai Y, Wang X, Li X, Pu C, Yuan H, Tang Y, et al. Management of catheter-related bladder discomfort in patients who underwent elective surgery. J Endourol 2015;29:640–9. 10.1089/end.2014.0670. 25335575.
6. Hatayama T, Mita K, Kohada Y, Fujiyama K, Tasaka R, Goriki A, et al. Efficacy of scheduled intravenous acetaminophen administration for catheter-related bladder discomfort in patients after transurethral resection of bladder tumors: a prospective randomized pilot study. Investig Clin Urol 2025;66:144–51. 10.4111/icu.20240357.

Article information Continued